TriangleSelinexor 40 mg (NCT06822972)
Selinexor 40 mg trial for Multiple Myeloma in Relapse (NCT06822972). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory myeloma after at least four treatment lines, including a proteasome inhibitor, an immunomodulator, and a CD38 antibody.
The idea: weekly oral selinexor keeps tumor-suppressing proteins inside cell nuclei. It is added after initial dosing of teclistamab, elranatamab, or talquetamab, antibodies that link immune cells to myeloma cells. Researchers assess safety and remaining disease. Treatment lasts up to 12 months unless disease progresses.
This phase 2 study plans 27 patients. Yubin Kang leads at Duke in Durham, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.